Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLamas Francis, David
dc.contributor.authorde Esteban Maciñeira, Elia
dc.contributor.authorSilva-Rodríguez, Paula
dc.contributor.authorPardo, Maria
dc.contributor.authorBande, Manuel F
dc.contributor.authorRodriguez-Fernandez, Carmen Antia
dc.date.accessioned2024-10-21T12:26:03Z
dc.date.available2024-10-21T12:26:03Z
dc.date.issued2024-07
dc.identifier.citationLamas-Francis D, Rodríguez-Fernández CA, de Esteban-Maciñeira E, Silva-Rodríguez P, Pardo M, Bande-Rodríguez M, et al. Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis. Cancers (Basel). 2024 Jul;16(14):2510.
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11351/12095
dc.descriptionDriver mutations; Survival; Uveal melanoma
dc.description.abstractThe prognosis of uveal melanoma is significantly influenced by the risk of metastasis, which varies according to clinical and genetic features. Driver mutations can predict the likelihood of disease progression and survival, although the data in the literature are inconsistent. This meta-analysis aimed to evaluate the prognostic significance of driver mutations, including GNAQ, GNA11, BAP1, and SF3B1, in the advancement of uveal melanoma. A comprehensive search of databases yielded relevant studies, and data from 13 studies (848 eyes) were synthesized to assess the impact of these mutations on metastasis-free survival. The BAP1 mutation and negative immunohistochemistry were associated with a higher risk of metastasis (logHR = 1.44, 95% CI 1.05–1.83). GNAQ, GNA11, and SF3B1 mutations did not show a significant increase in risk. In summary, BAP1 has proven to reliably predict the likelihood of disease progression in uveal melanoma, while further studies are needed to establish the significance of other driver mutations.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;16(14)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAnomalies cromosòmiques
dc.subjectÚvea - Càncer - Aspectes genètics
dc.subjectÚvea - Càncer - Prognosi
dc.subjectMetàstasi
dc.subject.meshMutation
dc.subject.meshUveal Neoplasms
dc.subject.mesh/genetics
dc.subject.meshProgression-Free Survival
dc.subject.meshNeoplasm Metastasis
dc.titleImpact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers16142510
dc.subject.decsmutación
dc.subject.decsneoplasias de la úvea
dc.subject.decs/genética
dc.subject.decssupervivencia libre de progresión
dc.subject.decsmetástasis neoplásica
dc.relation.publishversionhttps://doi.org/10.3390/cancers16142510
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Lamas-Francis D, de Esteban-Maciñeira E, Bande-Rodríguez M] Department of Ophthalmology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. [Rodríguez-Fernández CA] Servei d’Oftalmologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. FarmaChusLab Group, Health Research Institute of Santiago de Compostela (FIDIS), Santiago de Compostela, Spain. [Silva-Rodríguez P] Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain. Translational Ophthalmology Group, Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. [Pardo M] Obesidomics Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
dc.identifier.pmid39061150
dc.identifier.wos001278190600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record